Cargando…

Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer

BACKGROUND: Although a high level of thymidylate synthase (TS) expression in malignant tumours has been suggested to be related to a reduced sensitivity to the antifolate drug pemetrexed, no direct evidence for such an association has been demonstrated in non-small cell lung cancer (NSCLC). We have...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takezawa, K, Okamoto, I, Okamoto, W, Takeda, M, Sakai, K, Tsukioka, S, Kuwata, K, Yamaguchi, H, Nishio, K, Nakagawa, K
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3101907/ https://www.ncbi.nlm.nih.gov/pubmed/21487406 http://dx.doi.org/10.1038/bjc.2011.129

Ejemplares similares

Identification of thymidylate synthase as a potential therapeutic target for lung cancer
por: Takezawa, K, et al.
Publicado: (2010)

Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs
por: Iwasa, T, et al.
Publicado: (2010)

Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels
por: Giovannetti, E, et al.
Publicado: (2007)

Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients
por: Nishio, M, et al.
Publicado: (2005)

Molecular pathways involved in the synergistic interaction of the PKCβ inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells
por: Tekle, C, et al.
Publicado: (2008)

Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity
por: Etienne, M-C, et al.
Publicado: (2004)

Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status
por: Akashi, Y, et al.
Publicado: (2008)

Thymidylate Synthase as a Predictive Biomarker for Pemetrexed Response in NSCLC
por: Bukhari, Ali A., et al.
Publicado: (2013)

Expression of thymidylate synthase in human cells is an early G(1) event regulated by CDK4 and p16INK4A but not E2F
por: Le François, B G, et al.
Publicado: (2007)

The role of folate receptor alpha (FRα) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy
por: Nutt, J E, et al.
Publicado: (2010)

The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo
por: Akashi, Y, et al.
Publicado: (2007)

Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin
por: Giovannetti, E, et al.
Publicado: (2011)

Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer
por: Chamizo, Cristina, et al.
Publicado: (2015)

Thymidylate Synthase Expression Determines Pemetrexed Targets and Resistance Development in Tumour Cells
por: Buqué, Aitziber, et al.
Publicado: (2013)

A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer
por: Mercalli, A, et al.
Publicado: (2007)

Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells
por: Tanizaki, J, et al.
Publicado: (2012)

In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients
por: Mey, V, et al.
Publicado: (2006)

Significance of thymidylate synthase expression for resistance to pemetrexed in pulmonary adenocarcinoma
por: YANG, MIN, et al.
Publicado: (2014)

Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer
por: Kawabata, Shigeru, et al.
Publicado: (2014)

Fatty acid synthase expression associated with NAC1 is a potential therapeutic target in ovarian clear cell carcinomas
por: Rahman, M T, et al.
Publicado: (2012)

Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC
por: Wang, Xia, et al.
Publicado: (2013)

Comprehensive molecular exploration identified promoter DNA methylation of the CRBP1 gene as a determinant of radiation sensitivity in rectal cancer
por: Yokoi, K, et al.
Publicado: (2017)

C20orf20 (MRG-binding protein) as a potential therapeutic target for colorectal cancer
por: Yamaguchi, K, et al.
Publicado: (2010)

Upregulation of Thymidylate Synthase Induces Pemetrexed Resistance in Malignant Pleural Mesothelioma
por: Sato, Yuzo, et al.
Publicado: (2021)

Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma
por: Bilim, V, et al.
Publicado: (2009)

The pemetrexed-containing treatments in the non-small cell lung cancer, is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis
por: Wang, Lei, et al.
Publicado: (2014)

Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma
por: Yamamoto, J, et al.
Publicado: (2014)

Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: involvement in p53 regulation and cisplatin resistance
por: Leung, E L, et al.
Publicado: (2008)

HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer)
por: Plowright, L, et al.
Publicado: (2009)

Correlation between thymidylate synthase gene polymorphisms and efficacy of pemetrexed in advanced non-small cell lung cancer
por: HU, QIONG, et al.
Publicado: (2012)

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer
por: Nakayama, N, et al.
Publicado: (2008)

The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas
por: Seguin, F, et al.
Publicado: (2012)

Adenoviruses-mediated transduction of human oesophageal carcinoma cells with the interferon-λ genes produced anti-tumour effects
por: Li, Q, et al.
Publicado: (2011)

Insulin-like growth factor-binding protein 7 alters the sensitivity to interferon-based anticancer therapy in hepatocellular carcinoma cells
por: Tomimaru, Y, et al.
Publicado: (2010)

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer
por: Schmid, K, et al.
Publicado: (2010)

Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways
por: Zhang, Hao, et al.
Publicado: (2016)

Early detection of pemetrexed-induced inhibition of thymidylate synthase in non-small cell lung cancer with FLT-PET imaging
por: Chen, Xiao, et al.
Publicado: (2016)

The deubiquitinating enzyme UCHL1 promotes resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase
por: Ding, Xinyuan, et al.
Publicado: (2020)

Aurora B expression modulates paclitaxel response in non-small cell lung cancer
por: Al-Khafaji, Ahmed SK, et al.
Publicado: (2017)

Fatty acid synthase: a novel target for antiglioma therapy
por: Zhao, W, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_majctqoopls8r9rf5urdo1fau2